Cross-referencing clinical data
EarlyMyoviridae LH01
Myoviridae LH01.
A specific bacteriophage strain that targets harmful gut bacteria. Part of the PreforPro phage blend. Targets and destroys specific harmful bacteria in your gut, clearing space for beneficial microbes to flourish.
EarlyResearch strength15mgDaily amount
Reviewed March 2026
- Category
- General
- Also filed under
- Targets specific harmful gut bacteriaSupports microbiome balancePart of studied PreforPro blend
What Myoviridae LH01 is, and what it does.
- Does it work
- Interesting science, but only studied as part of a 4-phage blend (PreforPro). You can't isolate what this single phage does on its own. The concept is solid, the individual evidence isn't there yet.
- How much to take
- 15 mg as part of the PreforPro blend. There's no standalone dosing data for this individual phage. You'll only find it combined with the other three strains.
- The first dose
- Nothing noticeable on day one. Bacteriophages start working immediately at a microscopic level, but you won't feel the ecosystem shift for weeks.
- With regular use
- By weeks 3-4, some people in the PreforPro studies reported better digestion and less bloating. The phages keep working as long as their target bacteria are present, then naturally decline.
- How well tolerated
- Well tolerated. Bacteriophages are incredibly specific and can't infect human cells. Your gut already contains trillions of them. No known side effects or drug interactions.
- How it feels
- You won't feel it working directly. Think of it as invisible groundskeeping for your gut. The benefits show up as better digestion over time, not as a sensation you can point to.
About 15mg a day is the studied dose.
How much to take a dayLimited data
15mg
The doseThe daily amount the trials actually used. A product at this figure is dosed right where the research is.
Above 15mgMore capsules, not more effect. Rarely in a serving anyway.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Selectively reduces harmful gut bacteria
- Improves digestive comfort
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.
Questions people ask about Myoviridae LH01.
- Can a phage infect me?
- No. Bacteriophages are physically incapable of infecting human cells. They only target specific bacteria. It's like trying to plug a USB cable into a garden hose.
- Why can't I buy this phage alone?
- It only works as part of the 4-phage PreforPro cocktail. Each phage targets different bacteria. One phage alone has too narrow a range to be useful.
- Is this like taking an antibiotic?
- Similar concept, totally different execution. Antibiotics are carpet bombs (kill everything). Phages are sniper rifles (one specific target). Your good bacteria are well tolerated.
- How long do the phages survive in my gut?
- As long as their target bacteria exist, the phages replicate and persist. When targets run out, the phages naturally decline. It's a self-regulating system.
- Will this help with SIBO or IBS?
- Maybe, but don't count on it. The PreforPro studies showed modest GI improvements. It's not a treatment for diagnosed conditions.
- Do I need to refrigerate phage supplements?
- Check the label. Most PreforPro products are shelf-stable at room temperature, but some manufacturers recommend refrigeration for longer shelf life.
Nothing to show here, and the reason why.
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Myoviridae LH01 has none that clears that bar.
No pairing for Myoviridae LH01 has cleared review yet.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
Plays well withEstablished knowledge, not a trial
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Myoviridae LH01 + ProbioticsEstablished microbiology: bacteriophages and probiotic bacteria act on different populations, and phage host range is strain specific.
A lytic phage narrows a specific bacterial population while a probiotic adds a defined organism, so the two act from opposite directions on the same community. Phage host range is narrow and strain specific, which is the basis for pairing a coliphage with lactobacilli or bifidobacteria that it does not infect. Whether the combination produces a different community outcome than either alone is not something the available sourcing settles.
Myoviridae LH01 + Lactobacillus plantarumEstablished: coliphages adsorb to receptors on Gram-negative Escherichia coli envelopes and do not infect Gram-positive lactobacilli.
Phage attachment depends on specific surface receptors, and a phage selected against Escherichia coli has no receptor to bind on a Lactobacillus cell wall. That specificity is why coliphage preparations and lactobacillus cultures are formulated side by side. The pairing is a compatibility statement grounded in phage biology, not a demonstrated combined effect.
Myoviridae LH01 + Bifidobacterium longumEstablished phage host specificity: a coliphage cannot adsorb to a bifidobacterial cell surface.
Bifidobacteria present a different cell envelope from Escherichia coli and carry none of the receptors a coliphage recognises. Co-formulation therefore does not put the culture at risk from the phage. What the combination does to the wider community is a separate question the sourcing here does not answer.
Myoviridae LH01 + Bifidobacterium lactisEstablished phage host specificity across Gram-positive and Gram-negative envelopes.
Bifidobacterium lactis is unaffected by a phage selected against a Gram-negative host, which makes the two compatible in one capsule. Products pair them on exactly that basis. The compatibility is established microbiology; a combined outcome is not.
Myoviridae LH01 + InulinEstablished: prebiotic fructans are fermented preferentially by bifidobacteria and lactobacilli, not by phage.
Inulin feeds fermentative Gram-positive populations while a coliphage acts on a Gram-negative target, so the two push the community in the same direction by different means. Phages carry no metabolism of their own and do not consume the substrate. The pairing is a synbiotic-style rationale rather than a measured combination.
Myoviridae LH01 + FOS (fructooligosaccharides)Established prebiotic fermentation selectivity.
Short-chain fructans are fermented by bifidobacteria and lactobacilli and support their expansion. A lytic phage removes a specific competing population without touching the substrate. Combining a substrate for the desirable organisms with a narrow lytic agent is coherent design, and it has not been measured here as a combination.
Myoviridae LH01 + GOS (galactooligosaccharides)Established prebiotic fermentation selectivity in bifidobacteria.
Galactooligosaccharides are fermented efficiently by bifidobacteria, which are outside a coliphage's host range. The substrate and the phage act on different members of the community. This is a design rationale drawn from established microbiology.
Myoviridae LH01 + Resistant starchEstablished: resistant starch is fermented to short-chain fatty acids by colonic bacteria.
Resistant starch reaches the colon intact and is fermented to short-chain fatty acids, mainly by Gram-positive fermenters. A coliphage does not compete for that substrate and does not infect those fermenters. The two occupy different roles in the same formula.
Myoviridae LH01 + Partially hydrolyzed guar gumEstablished fermentable fibre behaviour in the colon.
Partially hydrolysed guar gum is a slowly fermented soluble fibre used where a gentler fermentation profile is wanted. It feeds bacteria that lie outside a coliphage's host range. The combination is a synbiotic-style pairing rather than a tested one.
Myoviridae LH01 + Sodium bicarbonateEstablished virology: phage capsids and genomes are damaged by low gastric pH.
Tailed phages lose infectivity in strongly acidic conditions, which is why oral phage preparations rely on enteric capsules or buffering to reach the colon intact. A bicarbonate buffer raises gastric pH transiently and is one of the approaches used for acid-labile actives. Whether it improves delivery for this specific preparation has not been measured here.
Myoviridae LH01 + Activated charcoalEstablished physical chemistry: activated charcoal adsorbs particles and macromolecules non-selectively.
Activated charcoal has a very large adsorptive surface and binds organic material without selectivity, including protein-coated particles the size of a phage. Taken at the same time it would be expected to remove the phage from the lumen before it reaches a host cell. Separating the two by several hours is the practical handling.
Myoviridae LH01 + Bentonite clayEstablished colloid science: clay minerals adsorb viruses and proteins onto their charged surfaces.
Clay minerals bind viral particles strongly enough that they are used industrially to strip viruses from water. A binder taken with a phage preparation would be expected to reduce the number of active particles reaching the colon. This is a physical interaction rather than a biological one, and spacing doses is the answer.
Myoviridae LH01 + PepsinEstablished biochemistry: phage capsids are protein assemblies and pepsin is a broad gastric protease.
A phage capsid is built entirely from protein subunits, and gastric pepsin cleaves protein at acidic pH. Supplemental pepsin adds to that proteolytic load at exactly the point where the phage is most vulnerable. An enteric capsule addresses the same problem from the formulation side.
Myoviridae LH01 + PancreatinEstablished biochemistry: pancreatic proteases hydrolyse the structural proteins that form a capsid and tail.
Trypsin and chymotrypsin in a pancreatic enzyme blend act on protein substrates in the small intestine, which is where a released phage particle travels. Adding protease at that stage is a plausible route to losing active particles before the colon. The interaction is mechanistic; it has not been quantified for this preparation.
Myoviridae LH01 + Digestive enzymesEstablished: protease-containing enzyme blends act on protein structures, and a phage particle is a protein shell.
Multi-enzyme blends usually carry protease activity across a range of pH values. That activity does not distinguish a dietary protein from a viral capsid protein. Where both are in one formula, delayed-release protection of the phage is the usual design answer.
Myoviridae LH01 + ButyrateEstablished: butyrate is the short-chain fatty acid product of colonic fermentation and the primary fuel of colonocytes.
Butyrate is what the desirable fermenters produce, and it is the main energy substrate for colonic epithelial cells. A phage preparation aims at the community composition upstream of that production. Supplying butyrate directly and shaping the community are different levers on the same endpoint.
Myoviridae LH01 + LactoferrinEstablished: lactoferrin sequesters iron and binds bacterial lipopolysaccharide on Gram-negative envelopes.
Lactoferrin binds iron tightly and interacts with the lipopolysaccharide layer of Gram-negative cells, which is the same envelope a coliphage targets. Whether that binding helps or hinders phage adsorption at the receptor is not established, so the direction of any real interaction is open. The pairing appears in gut formulas on the shared Gram-negative rationale.
Myoviridae LH01 + Saccharomyces boulardiiEstablished: a bacteriophage cannot infect a yeast, so the two are compatible in one formula.
Saccharomyces boulardii is a yeast and carries none of the bacterial surface receptors a phage recognises, so a phage cannot infect it. The two are paired in gut formulas on that compatibility. The compatibility is established biology; a combined effect is not something the available sourcing establishes.
Who should be cautious
Talk to a doctor before taking Myoviridae LH01 if any of these apply to you: Individual strain not studied in isolation, Bacteriophage therapy is still emerging. These are flags to check first, not effects Myoviridae LH01 is known to cause.
Not medical advice. Show the label to your pharmacist.Getting Myoviridae LH01 from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
Raw water sourcesAged cheeses
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
Lyophilised phage powderFreeze-dried phage particles held in a cryoprotectant matrix, typically a sugar such as trehalose or sucrose with a bulking carrier, filled into a capsule.Fits Shelf-stable capsule products where a dry, low-moisture format is needed.Trade-off Activity is stated as plaque-forming units, which decline over shelf life at a rate that depends on temperature and moisture ingress; the format offers no acid protection on its own.
What the strongest studies found
The essence, in one line each.
- In a 4-week randomised, double-blind, placebo-controlled trial in 68 healthy adults, adding a bacteriophage blend containing LH01 to a Bifidobacterium animalis subsp. lactis probiotic showed a within-group improvement in a self-reported gut symptom score (p = 0.01) and a larger rise in Lactobacillus and short-chain fatty acid producing bacteria than the probiotic alone.Randomised trial. Grubb et al., 2020 (Nutrients). PMID 32824480 ↗
These are the studies our verdict leans on, chosen from the 8 we read for Myoviridae LH01. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
